We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bicycle Therapeutics PLC | NASDAQ:BCYC | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.75% | 20.17 | 20.15 | 20.27 | 20.41 | 19.92 | 20.00 | 154,275 | 20:17:41 |
From Jun 2023 to Jun 2024
By Chris Wack
Bicycle Therapeutics shares were up 8% at $22.63 after the company said it will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the U.S. Food and Drug Administration.
The biotechnology company has aligned with the FDA on a Phase 2/3 registrational trial that has a design allowing for potential accelerated approval in untreated and previously treated metastatic bladder cancer.
Bicycle Therapeutics plans to initiate the trial in the first quarter of 2024.
The Phase 2/3 trial will assess BT8009 in untreated metastatic bladder cancer and previously treated metastatic bladder cancer. Discussions with the FDA about the design of the confirmatory trial for previously treated metastatic bladder cancer are ongoing.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 11, 2023 10:53 ET (14:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bicycle Therapeutics Chart |
1 Month Bicycle Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
